BLUETTI
Do I have to be an Amazon Prime Member to take advantage of BLUETTI Prime Day deals?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220710005073/en/
The short answer: nope. But if you’d like to grab the Prime Day sales only on Amazon , you’ll need to be an Amazon Prime Member.
BLUETTI confirms its annual shopping event - BLUETTI Prime Day date on July 5 - 15. To help you narrow things down, they've collected the best deals on their official website , from solar power stations, solar panels to various accessories worth your money.
The Best Prime Day Deals From BLUETTI
AC200P - The Most Popular 2kWh Solar Generator Now At The Lowest Price Ever - 1.699€ (was 1.999€)
Packed with a 2kW AC pure sine wave inverter, an enormous 2kWh capacity, and utilizing the most durable, safest LiFePO4 battery chemistry, the BLUETTI AC200P is undoubtedly the most cost-effective solar generator .
It can power all your needs from a household fridge to an 8.000 BTU portable air conditioner without breaking a sweat. Recharging by solar at a blistering speed up to 700W. You can juice up AC200P from zero to full in less than 4 hours with free, clean solar power alone!
AC200MAX - All-round Upgraded Power Beast - 2.099€ (was 2.399€)
With two expansion battery ports, the AC200MAX welcomes up to two BLUETTI B230 (2048Wh each) or B300 (3072Wh each) battery modules, allowing you to build on your system up to 8192Wh!
The AC200MAX allows up to 900W solar input and 400W via the AC wall charger, giving you a stunning 1300W total charging input to recharge it in less than 2 hours.
BLUETTI AC300 & B300 - Power Anything Imaginable - 3.899€ (was 4.299€)
Unlike any BLUETTI solar generator products, the AC300 has no built-in battery, bringing it unprecedented mobility and uniqueness. Every AC300 can accept up to 4 B300 (3072Wh each) battery modules, adding up to a groundbreaking 12288Wh capacity – Covering your whole family’s basic needs for DAYS during emergencies or power outages!
Time to plug into full-time solar life! BLUETTI AC300 is now capable of receiving 2400W of unrivaled solar charging input. The advanced MPPT controller lets you juice up a B300 (3072Wh) battery module as soon as 1,5hrs only with sunshine!
Other units highly recommended on BLUETTI UK & EU Prime Day 2022:
EB55 - 537Wh, 700W | Portable Solar Generator
- £549 (was £599);
EB70 - 716Wh, 1000W | Portable Power Station
- £649 (was £739);
B230 - 2048Wh LFP Expansion Battery
- £1399 (was £1499);
EP500Pro - 5100Wh, 3000W | Home Backup Power
- £5399 (was £5999)
AC200MAX & B230 - 4096Wh, 2200W | Portable Solar Generator
- £3199 (was £3499)
EB55 - 537Wh, 700W | Portable Solar Generator
- 599€ (was 649€);
EB70 - 716Wh, 1.000W | Portable Power Station
- 699€ (was 749€);
B230 - 2.048Wh LFP Expansion Battery
- 1.399€ (was 1.599€);
EP500Pro 5.100Wh, 3.000W | Home Backup Power
- 5.399€ (was 5.999€)
AC200MAX & 2/B230 & 3/SP200 - 6.144Wh, 2.200W | Bundles
- 6.394€ (was 8.249€)
About BLUETTI
With over 10 years of industry experience, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for everyone and the world. BLUETTI is making its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220710005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom